This work expands the application of cutaneous gene delivery of GLP1 for treating diseased states beyond obesity and diabetes and adds valuable supportive evidence of targeting GLP1 system as a novel treatment for AUD. The gene discussed is GCG; the disease is diabetes mellitus.